Objective To determine the dose-response curve of cisatracurium in patients with end-stage renal disease. Methods Forty patients with end stage renal disease were randomly divided into four groups, for each group, the dose were 20, 30, 40, 50µg/kg respectively. Twenty patients with normal neural and muscular funtion were randomly divided into four groups and received the same doses pattern. The dose-response curve was determined by single bolus of cisatracurium under midazolam-fentanyl intravenous anesthesia. Neuromuscular transmission monitor was used to measure the neuromuscular block effect after injection of cisatracurium, and the responses were defined in terms of the percentages of maximum supperssion in T1 of TOF of the adductor pollicis muscle. After log probit transformation of the data of dose and response, the dose-response curve of cisatracurium was then established by linear regression. Results The ED50, ED75, ED90 and ED95 of cisatracurium in patients with end stage kidney disease were 30.88μg/kg, 35.65μg/kg, 40.62μg/kg, 43.85μg/kg, in patients with normal neural and muscular funtion were 35.37μg/kg, 42.22μg/kg, 49.60μg/kg, 54.55μg/kg. Conclusion Neuromuscular disease is a common complication of end stage renal disease, and patients with end stage kidney disease is more sensitive to cisatracurium.